| Cat. No. |
Product Name |
Information |
| PC-45862 |
Palbociclib
CDK4/6 inhibitor
|
Palbociclib (PD0332991) is a potent and selective, orally bioavailable inhibitor of CDK4/6 with IC50 of 11 nM/16 nM. |
| PC-42052 |
SNS-032
CDK9 inhibitor
|
SNS-032 (BMS-387032) is a potent and selective inhibitor of CDK2/CDK7/CDK9 with IC50 of 48 nM/62 nM/4 nM, respectively. |
| PC-42616 |
Dinaciclib
CDK inhibitor
|
Dinaciclib (SCH 727965, MK-7965) is a potent and selective CDK inhibitor with IC50 of 1, 1, 3 and 4 nM against CDK2, CDK5, CDK1 and CDK9, respectively. |
| PC-45792 |
Roscovitine
CDK inhibitor
|
Roscovitine ((R)-Roscovitine, Seliciclib, CYC202) is a potent and selective CDK inhibitor with IC50 of 0.2 uM, 0.65 uM, and 0.7 uM for CDK5, Cdc2, and CDK2, respectively. |
| PC-42036 |
LY3177833
CDC7 inhibitor
|
LY3177833 is a potent and selective CDC7 inhibitor with IC50 of 3.3 nM. |
| PC-42060 |
AZD-5438
CDK1/2/9 inhibitor
|
AZD-5438 (AZD5438) potent and oral inhibitor of CDK1/2/9 with IC50 of 16/6/20 nM, respectively. |
| PC-42425 |
Senexin B
CDK8/CDK19 inhibitor
|
Senexin B (SNX2-1-165) is a highly potent, selective and orally available CDK8/CDK19 inhibitor with IC50 of 24-50 nM. |
| PC-42527 |
JNJ-7706621
CDK/Aurora inhibitor
|
JNJ-7706621 is a potent, dual CDK/Aurora kinase inhibitor with IC50 of 9/4/11/15 nM for CDK1/CDK2/Aurora A/Aurora B respectively. |
| PC-27675 |
RGB-286638 free base
CDK inhibitor
|
RGB-286638 free base is a small-molecule multi-targeted cyclin-dependent kinase (CDK) inhibitor with IC50 of 1-5 nM for cyclin T1-CDK9, cyclin B1-CDK1, cyclin E-CDK2, cyclin D1-CDK4, cyclin E-CDK3, and p35-CDK5. |
| PC-27637 |
Cucurbitacin E
Cyclin B1 inhibitor
|
Cucurbitacin E (α-elaterin) is a strong antifeedant natural compound with the ability to disrupt cell actin and cell adhesion, induces CRC G2/M phase arrest via cell division cycle gene 2 (CDC2) downregulation and dissociation of the cyclin B1/CDC2 complex. |
| PC-27526 |
CID-078
Cyclin A/B-RxL inhibitor
|
CID-078 is a highly potent, first-in-class, oral macrocycle cyclin A/B-RxL inhibitor with IC50 of <0.02 uM for both cyclin A and cyclin B in FP assays, Kd of 1.1 nM and 0.83 nM for cyclin A and cyclin B respectively. |
| PC-27520 |
TK22
EndMT inhibitor, Multikinases inhibitor
|
TK22 is a small molecule that selectively erases Endothelial-to-mesenchymal transition (EndMT)-competent endothelial state and reverses experimental pulmonary hypertension, inhibits interphase cell-cycle kinases CDK2/3/4/6 node as well as a pro-mesenchymal node of AMPK-related kinases (NUAK1 and SIK1/2/3) together with PDGFRβ and MLK3. |
